Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 183

1.

Early detection and treatment strategies for breast cancer in low-income and upper middle-income countries: a modelling study.

Birnbaum JK, Duggan C, Anderson BO, Etzioni R.

Lancet Glob Health. 2018 Aug;6(8):e885-e893. doi: 10.1016/S2214-109X(18)30257-2.

2.

Undetectable prostate-specific antigen after short-course androgen deprivation therapy for biochemically recurrent patients correlates with metastasis-free survival and prostate cancer-specific survival.

Lim DM, Gulati R, Aleshin-Guendel S, Gawne A, Wingate JT, Cheng HH, Etzioni R, Yu EY.

Prostate. 2018 Jul 10. doi: 10.1002/pros.23666. [Epub ahead of print]

PMID:
29987912
3.

Beyond classic risk adjustment: Socioeconomic status and hospital performance in urologic oncology surgery.

Odisho AY, Etzioni R, Gore JL.

Cancer. 2018 Jun 15. doi: 10.1002/cncr.31587. [Epub ahead of print]

PMID:
29905929
4.

Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society.

Wolf AMD, Fontham ETH, Church TR, Flowers CR, Guerra CE, LaMonte SJ, Etzioni R, McKenna MT, Oeffinger KC, Shih YT, Walter LC, Andrews KS, Brawley OW, Brooks D, Fedewa SA, Manassaram-Baptiste D, Siegel RL, Wender RC, Smith RA.

CA Cancer J Clin. 2018 May 30. doi: 10.3322/caac.21457. [Epub ahead of print]

5.

Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials.

Tsodikov A, Gulati R, Etzioni R.

Ann Intern Med. 2018 Apr 17;168(8):608-609. doi: 10.7326/L17-0738. No abstract available.

PMID:
29677262
6.

When Clinical Trials Disagree.

Etzioni R, Gulati R.

J Urol. 2018 Mar 1. pii: S0022-5347(18)42396-8. doi: 10.1016/j.juro.2018.02.3084. [Epub ahead of print] No abstract available.

PMID:
29496471
7.

Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes.

Cooperberg MR, Brooks JD, Faino AV, Newcomb LF, Kearns JT, Carroll PR, Dash A, Etzioni R, Fabrizio MD, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW, Zheng Y.

Eur Urol. 2018 Aug;74(2):211-217. doi: 10.1016/j.eururo.2018.01.017. Epub 2018 Feb 9.

PMID:
29433975
8.

Estimating the frequency of indolent breast cancer in screening trials.

Shen Y, Dong W, Gulati R, Ryser MD, Etzioni R.

Stat Methods Med Res. 2018 Jan 1:962280217754232. doi: 10.1177/0962280217754232. [Epub ahead of print]

PMID:
29402176
9.

Racial disparities in prostate cancer survival in a screened population: Reality versus artifact.

Kaur D, Ulloa-Pérez E, Gulati R, Etzioni R.

Cancer. 2018 Apr 15;124(8):1752-1759. doi: 10.1002/cncr.31253. Epub 2018 Jan 25.

PMID:
29370459
10.

The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials.

de Koning HJ, Gulati R, Moss SM, Hugosson J, Pinsky PF, Berg CD, Auvinen A, Andriole GL, Roobol MJ, Crawford ED, Nelen V, Kwiatkowski M, Zappa M, Luján M, Villers A, de Carvalho TM, Feuer EJ, Tsodikov A, Mariotto AB, Heijnsdijk EAM, Etzioni R.

Cancer. 2018 Mar 15;124(6):1197-1206. doi: 10.1002/cncr.31178. Epub 2017 Dec 6.

PMID:
29211316
11.

Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts.

Inoue LYT, Lin DW, Newcomb LF, Leonardson AS, Ankerst D, Gulati R, Carter HB, Trock BJ, Carroll PR, Cooperberg MR, Cowan JE, Klotz LH, Mamedov A, Penson DF, Etzioni R.

Ann Intern Med. 2018 Jan 2;168(1):1-9. doi: 10.7326/M17-0548. Epub 2017 Nov 28.

12.

Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials.

Tsodikov A, Gulati R, Heijnsdijk EAM, Pinsky PF, Moss SM, Qiu S, de Carvalho TM, Hugosson J, Berg CD, Auvinen A, Andriole GL, Roobol MJ, Crawford ED, Nelen V, Kwiatkowski M, Zappa M, Luján M, Villers A, Feuer EJ, de Koning HJ, Mariotto AB, Etzioni R.

Ann Intern Med. 2017 Oct 3;167(7):449-455. doi: 10.7326/M16-2586. Epub 2017 Sep 5.

13.

A Framework for Treatment Decision Making at Prostate Cancer Recurrence.

Lange JM, Trock BJ, Gulati R, Etzioni R.

Med Decis Making. 2017 Nov;37(8):905-913. doi: 10.1177/0272989X17711913. Epub 2017 May 31.

PMID:
28564551
14.

Estimation of the Number of Women Living with Metastatic Breast Cancer in the United States.

Mariotto AB, Etzioni R, Hurlbert M, Penberthy L, Mayer M.

Cancer Epidemiol Biomarkers Prev. 2017 Jun;26(6):809-815. doi: 10.1158/1055-9965.EPI-16-0889. Epub 2017 May 18.

15.

Is prostate cancer different in black men? Answers from 3 natural history models.

Tsodikov A, Gulati R, de Carvalho TM, Heijnsdijk EAM, Hunter-Merrill RA, Mariotto AB, de Koning HJ, Etzioni R.

Cancer. 2017 Jun 15;123(12):2312-2319. doi: 10.1002/cncr.30687. Epub 2017 Apr 24.

16.

Both a stage shift and changes in stage-specific survival have contributed to reductions in breast cancer mortality.

Duffy SW, Etzioni R, Sasieni P.

Evid Based Med. 2017 Apr;22(2):76. doi: 10.1136/ebmed-2016-110632. Epub 2017 Feb 22. No abstract available.

PMID:
28228386
17.

Demographic changes in breast cancer incidence, stage at diagnosis and age associated with population-based mammographic screening.

Verdial FC, Etzioni R, Duggan C, Anderson BO.

J Surg Oncol. 2017 Apr;115(5):517-522. doi: 10.1002/jso.24579. Epub 2017 Feb 14.

18.

Missteps in Current Estimates of Cancer Overdiagnosis.

Lee CI, Etzioni R.

Acad Radiol. 2017 Feb;24(2):226-229. doi: 10.1016/j.acra.2016.05.020. Epub 2016 Nov 25. Review.

19.

Screening Men at Increased Risk for Prostate Cancer Diagnosis: Model Estimates of Benefits and Harms.

Gulati R, Cheng HH, Lange PH, Nelson PS, Etzioni R.

Cancer Epidemiol Biomarkers Prev. 2017 Feb;26(2):222-227. doi: 10.1158/1055-9965.EPI-16-0434. Epub 2016 Oct 14.

20.

Advanced Imaging and Receipt of Guideline Concordant Care in Women with Early Stage Breast Cancer.

Loggers ET, Buist DS, Gold LS, Zeliadt S, Hunter Merrill R, Etzioni R, Ramsey SD, Sullivan SD, Kessler L.

Int J Breast Cancer. 2016;2016:2182985. doi: 10.1155/2016/2182985. Epub 2016 Jul 25.

21.

Conditions for Valid Empirical Estimates of Cancer Overdiagnosis in Randomized Trials and Population Studies.

Gulati R, Feuer EJ, Etzioni R.

Am J Epidemiol. 2016 Jul 15;184(2):140-7. doi: 10.1093/aje/kwv342. Epub 2016 Jun 29.

22.

NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016.

Carroll PR, Parsons JK, Andriole G, Bahnson RR, Castle EP, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Farrington T, Hemstreet GP 3rd, Kawachi MH, Kim S, Lange PH, Loughlin KR, Lowrance W, Maroni P, Mohler J, Morgan TM, Moses KA, Nadler RB, Poch M, Scales C, Shaneyfelt TM, Smaldone MC, Sonn G, Sprenkle P, Vickers AJ, Wake R, Shead DA, Freedman-Cass DA.

J Natl Compr Canc Netw. 2016 May;14(5):509-19.

PMID:
27160230
23.

A Matched Cohort Analysis of Prostate Cancer Screening in Younger Men in Sweden.

Gulati R, Etzioni R.

Eur Urol. 2017 Jan;71(1):53-54. doi: 10.1016/j.eururo.2016.04.006. Epub 2016 Apr 16. No abstract available.

PMID:
27090976
24.

Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies.

Roth JA, Gulati R, Gore JL, Cooperberg MR, Etzioni R.

JAMA Oncol. 2016 Jul 1;2(7):890-8. doi: 10.1001/jamaoncol.2015.6275.

25.

Recent Trends in PSA Testing and Prostate Cancer Incidence: A Look at Context.

Etzioni R, Gulati R.

JAMA Oncol. 2016 Jul 1;2(7):955-6. doi: 10.1001/jamaoncol.2015.6310. No abstract available.

PMID:
27010657
26.

Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer.

Kumar A, Coleman I, Morrissey C, Zhang X, True LD, Gulati R, Etzioni R, Bolouri H, Montgomery B, White T, Lucas JM, Brown LG, Dumpit RF, DeSarkar N, Higano C, Yu EY, Coleman R, Schultz N, Fang M, Lange PH, Shendure J, Vessella RL, Nelson PS.

Nat Med. 2016 Apr;22(4):369-78. doi: 10.1038/nm.4053. Epub 2016 Feb 29.

27.

Treatment Trends for Stage I Testicular Seminoma in an Equal-Access Medical System.

Wingate JT, Etzioni R, Macdonald DM, Brand TC.

Clin Genitourin Cancer. 2016 Oct;14(5):438-443. doi: 10.1016/j.clgc.2015.12.021. Epub 2015 Dec 21.

PMID:
26794393
28.

The Effect of Treatment Advances on the Mortality Results of Breast Cancer Screening Trials: A Microsimulation Model.

Birnbaum J, Gadi VK, Markowitz E, Etzioni R.

Ann Intern Med. 2016 Feb 16;164(4):236-43. doi: 10.7326/M15-0754. Epub 2016 Jan 12.

29.

Active Surveillance for Ductal Carcinoma in Situ: Shining Light Into the Modeling Abyss.

Etzioni R, Gulati R.

J Natl Cancer Inst. 2015 Dec 17;108(5). pii: djv378. doi: 10.1093/jnci/djv378. Print 2016 May. No abstract available.

PMID:
26683406
30.

NCCN Clinical Practice Guidelines Prostate Cancer Early Detection, Version 2.2015.

Carroll PR, Parsons JK, Andriole G, Bahnson RR, Barocas DA, Castle EP, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Farrington T, Hemstreet GP 3rd, Kawachi MH, Lange PH, Loughlin KR, Lowrance W, Maroni P, Mohler J, Morgan TM, Nadler RB, Poch M, Scales C, Shaneyfelt TM, Smaldone MC, Sonn G, Sprenke P, Vickers AJ, Wake R, Shead DA, Freedman-Cass D.

J Natl Compr Canc Netw. 2015 Dec;13(12):1534-61.

PMID:
26656522
31.

Recognizing the Limitations of Cancer Overdiagnosis Studies: A First Step Towards Overcoming Them.

Etzioni R, Gulati R.

J Natl Cancer Inst. 2015 Nov 18;108(3). pii: djv345. doi: 10.1093/jnci/djv345. Print 2016 Mar. Review.

32.

Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society.

Oeffinger KC, Fontham ET, Etzioni R, Herzig A, Michaelson JS, Shih YC, Walter LC, Church TR, Flowers CR, LaMonte SJ, Wolf AM, DeSantis C, Lortet-Tieulent J, Andrews K, Manassaram-Baptiste D, Saslow D, Smith RA, Brawley OW, Wender R; American Cancer Society.

JAMA. 2015 Oct 20;314(15):1599-614. doi: 10.1001/jama.2015.12783. Erratum in: JAMA. 2016 Apr 5;315(13):1406.

33.

Comparative Effectiveness of Biomarkers to Target Cancer Treatment: Modeling Implications for Survival and Costs.

Birnbaum JK, Ademuyiwa FO, Carlson JJ, Mallinger L, Mason MW, Etzioni R.

Med Decis Making. 2016 Jul;36(5):594-603. doi: 10.1177/0272989X15601998. Epub 2015 Aug 24.

34.

Difference in Association of Obesity With Prostate Cancer Risk Between US African American and Non-Hispanic White Men in the Selenium and Vitamin E Cancer Prevention Trial (SELECT).

Barrington WE, Schenk JM, Etzioni R, Arnold KB, Neuhouser ML, Thompson IM Jr, Lucia MS, Kristal AR.

JAMA Oncol. 2015 Jun;1(3):342-9. doi: 10.1001/jamaoncol.2015.0513. Erratum in: JAMA Oncol. 2015 Jun;1(3):322.

35.

Effect of Screening Mammography on Cancer Incidence and Mortality.

Elmore JG, Etzioni R.

JAMA Intern Med. 2015 Sep;175(9):1490-1. doi: 10.1001/jamainternmed.2015.3056. No abstract available.

PMID:
26147329
36.

Predictors of preoperative MRI for breast cancer: differences by data source.

Loggers ET, Gao H, Gold LS, Kessler L, Etzioni R, Buist DS; ADVICE Investigators.

J Comp Eff Res. 2015 May 11:1-12. [Epub ahead of print]

37.

Prospective quality-of-life outcomes for low-risk prostate cancer: Active surveillance versus radical prostatectomy.

Jeldres C, Cullen J, Hurwitz LM, Wolff EM, Levie KE, Odem-Davis K, Johnston RB, Pham KN, Rosner IL, Brand TC, L'Esperance JO, Sterbis JR, Etzioni R, Porter CR.

Cancer. 2015 Jul 15;121(14):2465-73. doi: 10.1002/cncr.29370. Epub 2015 Apr 6.

38.

Models in the development of clinical practice guidelines.

Habbema JD, Wilt TJ, Etzioni R.

Ann Intern Med. 2015 Apr 7;162(7):530-1. doi: 10.7326/L15-5075-2. No abstract available.

PMID:
25845011
39.

Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canary-Early Detection Research Network Active Surveillance Biopsy Risk Calculator.

Ankerst DP, Xia J, Thompson IM Jr, Hoefler J, Newcomb LF, Brooks JD, Carroll PR, Ellis WJ, Gleave ME, Lance RS, Nelson PS, Wagner AA, Wei JT, Etzioni R, Lin DW.

Eur Urol. 2015 Dec;68(6):1083-8. doi: 10.1016/j.eururo.2015.03.023. Epub 2015 Mar 25.

40.

Measures of survival benefit in cancer drug development and their limitations.

Etzioni R, Gulati R, Lin DW.

Urol Oncol. 2015 Mar;33(3):122-7. doi: 10.1016/j.urolonc.2014.11.002. Review.

41.

Projecting Benefits and Harms of Novel Cancer Screening Biomarkers: A Study of PCA3 and Prostate Cancer.

Birnbaum JK, Feng Z, Gulati R, Fan J, Lotan Y, Wei JT, Etzioni R.

Cancer Epidemiol Biomarkers Prev. 2015 Apr;24(4):677-82. doi: 10.1158/1055-9965.EPI-14-1224. Epub 2015 Jan 22.

42.

The diffusion of docetaxel in patients with metastatic prostate cancer.

Unger JM, Hershman DL, Martin D, Etzioni RB, Barlow WE, LeBlanc M, Ramsey SR.

J Natl Cancer Inst. 2014 Dec 24;107(2). pii: dju412. doi: 10.1093/jnci/dju412. Print 2015 Feb.

43.

Models in the development of clinical practice guidelines.

Habbema JD, Wilt TJ, Etzioni R, Nelson HD, Schechter CB, Lawrence WF, Melnikow J, Kuntz KM, Owens DK, Feuer EJ.

Ann Intern Med. 2014 Dec 2;161(11):812-8. doi: 10.7326/M14-0845.

PMID:
25437409
44.

A reality check for overdiagnosis estimates associated with breast cancer screening.

Etzioni R, Xia J, Hubbard R, Weiss NS, Gulati R.

J Natl Cancer Inst. 2014 Oct 31;106(12). pii: dju315. doi: 10.1093/jnci/dju315. Print 2014 Dec.

45.

Tumor marker usage and medical care costs among older early-stage breast cancer survivors.

Ramsey SD, Henry NL, Gralow JR, Mirick DK, Barlow W, Etzioni R, Mummy D, Thariani R, Veenstra DL.

J Clin Oncol. 2015 Jan 10;33(2):149-55. doi: 10.1200/JCO.2014.55.5409. Epub 2014 Oct 20.

46.

Overdetection of recurrence after radical prostatectomy: estimates based on patient and tumor characteristics.

Xia J, Trock BJ, Gulati R, Mallinger L, Cooperberg MR, Carroll PR, Carter HB, Etzioni R.

Clin Cancer Res. 2014 Oct 15;20(20):5302-10. doi: 10.1158/1078-0432.CCR-13-3366.

47.

Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines.

Carroll PR, Parsons JK, Andriole G, Bahnson RR, Barocas DA, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Giri VN, Hemstreet GP 3rd, Kawachi MH, Lange PH, Loughlin KR, Lowrance W, Maroni P, Mohler J, Morgan TM, Nadler RB, Poch M, Scales C, Shanefelt TM, Vickers AJ, Wake R, Shead DA, Ho M; National comprehensive cancer network.

J Natl Compr Canc Netw. 2014 Sep;12(9):1211-9; quiz 1219.

PMID:
25190691
48.

National trends in the management of low and intermediate risk prostate cancer in the United States.

Weiner AB, Patel SG, Etzioni R, Eggener SE.

J Urol. 2015 Jan;193(1):95-102. doi: 10.1016/j.juro.2014.07.111. Epub 2014 Aug 5.

PMID:
25106900
49.

Expected population impacts of discontinued prostate-specific antigen screening.

Gulati R, Tsodikov A, Etzioni R, Hunter-Merrill RA, Gore JL, Mariotto AB, Cooperberg MR.

Cancer. 2014 Nov 15;120(22):3519-26. doi: 10.1002/cncr.28932. Epub 2014 Jul 25.

50.

Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits.

Lansdorp-Vogelaar I, Gulati R, Mariotto AB, Schechter CB, de Carvalho TM, Knudsen AB, van Ravesteyn NT, Heijnsdijk EA, Pabiniak C, van Ballegooijen M, Rutter CM, Kuntz KM, Feuer EJ, Etzioni R, de Koning HJ, Zauber AG, Mandelblatt JS.

Ann Intern Med. 2014 Jul 15;161(2):104-12. doi: 10.7326/M13-2867.

Supplemental Content

Loading ...
Support Center